» Articles » PMID: 6282411

Structural Factors Influencing the Ability of Compounds to Inhibit Hydroxyapatite Formation

Overview
Specialty Pathology
Date 1982 Mar 1
PMID 6282411
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

For a compound to inhibit potently the transformation of amorphous calcium phosphate into hydroxyapatite, it is suggested that the minimum structural requirement is a phosphate group and, at some other position, either another phosphate group preferably or a carboxylic moiety. Primary amino groups abolish inhibitor potential. Inhibitor potency is modified by various secondary factors, including the number and proximity of active groups, their stereochemistry, steric factors, the lability of the molecule, and in special instances its lipophilicity. Parameters used to monitor the transformation indicate that inhibitors can be grouped into two classes, and it is suggested that this is because one class acts as a hydroxyapatite crystal growth inhibitor. The close proximity of two phosphate groups or of a phosphate and multiple carboxylic groups is proposed to determine in part whether or not a compound acts as a crystal growth inhibitor. Further, bulky side groups render a molecule inactive as a crystal growth poison, although it will still inhibit by other mechanisms.

Citing Articles

The role of inhibition by phosphocitrate and its analogue in chondrocyte differentiation and subchondral bone advance in Hartley guinea pigs.

Sun Y, Kiraly A, Cox M, Mauerhan D, Hanley Jr E Exp Ther Med. 2018; 15(4):3320-3328.

PMID: 29545850 PMC: 5841021. DOI: 10.3892/etm.2018.5846.


Bone-seeking agents for the treatment of bone disorders.

Cawthray J, Wasan E, Wasan K Drug Deliv Transl Res. 2017; 7(4):466-481.

PMID: 28589453 DOI: 10.1007/s13346-017-0394-3.


Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis.

Sun Y, Haines N, Roberts A, Ruffolo M, Mauerhan D, Mihalko K BMC Musculoskelet Disord. 2015; 16:270.

PMID: 26424660 PMC: 4588234. DOI: 10.1186/s12891-015-0724-x.


Biological activities of phosphocitrate: a potential meniscal protective agent.

Sun Y, Roberts A, Mauerhan D, Sun A, Norton H, Hanley Jr E Biomed Res Int. 2013; 2013:726581.

PMID: 23936839 PMC: 3726015. DOI: 10.1155/2013/726581.


The deep-sea natural products, biogenic polyphosphate (Bio-PolyP) and biogenic silica (Bio-Silica), as biomimetic scaffolds for bone tissue engineering: fabrication of a morphogenetically-active polymer.

Wang X, Schroder H, Feng Q, Draenert F, Muller W Mar Drugs. 2013; 11(3):718-46.

PMID: 23528950 PMC: 3705367. DOI: 10.3390/md11030718.


References
1.
Meyer J, Nancollas G . The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite. Calcif Tissue Res. 1973; 13(4):295-303. DOI: 10.1007/BF02015419. View

2.
Kawasaki T . Theory of chromatography of rigid molecules on hydroxyapatite columns with small loads. I. The case when virtually all molecules are adsorbed on to a single type of crystal site through a single type of adsorption group. J Chromatogr. 1974; 93(2):313-35. DOI: 10.1016/s0021-9673(01)85396-6. View

3.
Nancollas G, Mohan M . The growth of hydroxyapatite crystals. Arch Oral Biol. 1970; 15(8):731-45. DOI: 10.1016/0003-9969(70)90037-3. View

4.
Termine J, Peckauskas R, Posner A . Calcium phosphate formation in vitro. II. Effects of environment on amorphous-crystalline transformation. Arch Biochem Biophys. 1970; 140(2):318-25. DOI: 10.1016/0003-9861(70)90072-x. View

5.
Robertson W, Fleisch H . The effect of imidodiphosphate (P-N-P) on the precipitation and dissolution of calcium phosphate in vitro. Biochim Biophys Acta. 1970; 222(3):677-80. DOI: 10.1016/0304-4165(70)90198-4. View